Loading…

Effect of cyclic AMP level reduction on human neutrophil responses to formylated peptides

The increase in human neutrophil cyclic adenosine monophosphate (cAMP) levels evoked by formylated peptides is significantly reduced in the presence of MDL 12330A, SQ 22536, GDPβS and clonidine, which inhibit the adenylyl cyclase system by acting at different sites in this enzyme complex. A similar...

Full description

Saved in:
Bibliographic Details
Published in:Cellular signalling 1996-06, Vol.8 (4), p.269-277
Main Authors: Spisani, Susanna, Pareschi, Maria Cristina, Buzzi, Marco, Colamussi, Maria Luisa, Biondi, Carla, Traniello, Serena, Zecchini, Giampiero Pagani, Paradisi, Mario Paglialunga, Torrini, Ines, Ferretti, Maria Enrica
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The increase in human neutrophil cyclic adenosine monophosphate (cAMP) levels evoked by formylated peptides is significantly reduced in the presence of MDL 12330A, SQ 22536, GDPβS and clonidine, which inhibit the adenylyl cyclase system by acting at different sites in this enzyme complex. A similar effect is exerted by adenosine deaminase and dipyridamole, which alter the extracellular adenosine concentration. Neutrophil preincubation with adenylyl cyclase inhibitors or dipyridamole reduces chemotaxis and superoxide anion production triggered by peptides; adenosine deaminase, on the contrary, has no effect on neutrophil responses. Our results seem to indicate that: (1) the peptide-induced increase in neutrophil cAMP is due mainly to an action on the adenylyl cyclase system; (2) an enhancement of this cyclic nucleotide, even slight and necessarily transient, is required for cchemotaxis and Oz production induced in neutrophils by formylated peptides; and (3) cAMP does not represent the crucial second messenger for adenosine in the modulation of neutrophil responses.
ISSN:0898-6568
1873-3913
DOI:10.1016/0898-6568(96)00049-6